Monday 22 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Optibiotix - P&G deal not brown bread: Boss Steve O'Hara explains

By HotStockRockets | Saturday 11 March 2017

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

If Optibiotix (OPTI) said that 2 +2 =4 then some folks would start banging on about how that means it cant equal three. There is no pleasing them. Thus after the cracking deal with Sacco announced earlier this week all some folks wanted to talk about was P&G.

A reader of ShareProphets posts:

You have probably released by now a HSR update on Optibiotix after today's great announcement. Hopefully the start of a steady news flow now. Re the cholesterol product, Sacco for Europe, possibly/hopefully Tata for Asia? But maybe not P&G for America after today's SoH interview. Do you know if P&G are still in the mix?

Over to Steve O'Hara the Optibiotix boss:

I cannot give away any confidential information but we haven’t excluded any partner with whom we have ongoing arrangements from future agreements.

We believe the opportunity is greater than initially anticipated and as reported in RNS’s have broadened our IP protection to include hypertension reduction and formulations containing our LP-LDL strain for a wide range of cardiovascular illnesses.

This extends the scope beyond agreements made before the human study and broadens the opportunities open to us with a wider range of partners in both consumer health and pharma. Most of these partners do not have manufacturing or formulation facilities. The appointment of Sacco in Europe, and other partners in Asia and USA facilitates agreements with a number of partners both large and small who have the necessary sales capability to fully exploit the opportunity open to us across the world.


Okay so "ongoing arrangement" leads any rational chap to conclude that Optibiotix is now in business with Sacco, P&G and of course Tata. More big names will follow soon and these names can deliver very material sales indeed. That is why this remains so exciting.

Buy at up to 80p - target to sell well over 100p

This article first appeared on HotStockRockets - its always paying customers first.  If you missed out on Wednesday's red hot share tip, fear not there are TWO more on the way within the next three weeks and you can access both and all of our archive for just £5, HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI


Comments are turned off for this article.

Site by Everywhen